Literature DB >> 30712198

Efficacy of self-administered complex decongestive therapy on breast cancer-related lymphedema: a single-blind randomized controlled trial.

M B Ligabue1, I Campanini2,3, P Veroni1, A Cepelli1, M Lusuardi4, A Merlo5.   

Abstract

PURPOSE: After surgery, breast cancer-related lymphedema (BCRL) is a frequent chronic condition. The complex decongestive therapy (CDT) delivered by physiotherapists at hospitals is the state-of-the-art treatment choice. As lymphedema requires continuous management, we designed a 1-month-long course to train women to professionally carry out a self-administered CDT (saCDT) and tested its efficacy while keeping the benefits of CDT.
METHODS: Consecutive patients treated with CDT over a 1-year period at an Italian facility were randomly assigned to either experimental (EXP, saCDT course) or control (CTRL, usual care) group. Women were assessed before, at 1, and 6 months from enrolment. Pain assessed by the numerical pain rating scale (NPRS) was the primary outcome. Arm asymmetry assessed by the excess limb volume (ELV) was the secondary outcome. Outcome variations were compared to their MCID to classify women as improved, stable, or worsened.
RESULTS: Forty-one women were included. The proportion of stable or improved women was significantly different between EXP and CTRL groups at 6 months after enrolment for both arm pain (p = 0.01) and asymmetry (p < 0.01). Noteworthy, only one EXP woman had worsened after 6 months. NPRS significantly decreased in the EXP group only, with a median variation of 2 points. Arm ELV significantly decreased with respect to the baseline value in the EXP group only, with a median reduction of 8%.
CONCLUSIONS: Teaching saCDT to women with BCRL is effective in maintaining or improving the benefits of CDT and can be used as a self-care tool in the management of BCRL.

Entities:  

Keywords:  Breast cancer; Complex decongestive therapy; Lymphedema; Self-care

Mesh:

Year:  2019        PMID: 30712198     DOI: 10.1007/s10549-019-05136-9

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  6 in total

1.  Features, Predictors, and Treatment of Breast Cancer-related Lymphedema.

Authors:  Xiaochen Zhang; Jill M Oliveri; Electra D Paskett
Journal:  Curr Breast Cancer Rep       Date:  2020-09-09

2.  Interventions for Breast Cancer-Related Lymphedema: Clinical Practice Guideline From the Academy of Oncologic Physical Therapy of APTA.

Authors:  Claire Davies; Kimberly Levenhagen; Kathryn Ryans; Marisa Perdomo; Laura Gilchrist
Journal:  Phys Ther       Date:  2020-07-19

3.  Simultaneous Ipsilateral Vascularized Lymph Node Transplantation and Contralateral Lymphovenous Anastomosis in Bilateral Extremity Lymphedema with Different Severities.

Authors:  M-H Cheng; R Tee; C Chen; C-Y Lin; M Pappalardo
Journal:  Ann Surg Oncol       Date:  2020-06-18       Impact factor: 5.344

4.  Self-administration of complex decongestive therapy facilitated by the mobile application WeChat improves lymphedema and quality of life in breast cancer survivors: an observational study.

Authors:  Xu Liang; Miaoning You; Cuiju Wen; Fengzhen Hou; Jingjing Kang; Zhihua Lv; Jun Tian
Journal:  Ann Transl Med       Date:  2022-02

Review 5.  Surgical Treatment and Rehabilitation Strategies for Upper and Lower Extremity Lymphedema: A Comprehensive Review.

Authors:  Alessandro de Sire; Luigi Losco; Lorenzo Lippi; Davide Spadoni; Juste Kaciulyte; Gokhan Sert; Paola Ciamarra; Marco Marcasciano; Roberto Cuomo; Alberto Bolletta; Marco Invernizzi; Emanuele Cigna
Journal:  Medicina (Kaunas)       Date:  2022-07-19       Impact factor: 2.948

6.  Efficacy of physical therapy interventions on quality of life and upper quadrant pain severity in women with post-mastectomy pain syndrome: a systematic review and meta-analysis.

Authors:  Priya Kannan; Hiu Ying Lam; Tsz Kiu Ma; Chiu Ngai Lo; Ting Yan Mui; Wing Yan Tang
Journal:  Qual Life Res       Date:  2021-06-29       Impact factor: 4.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.